Valion Bio (TIVC) Change in Receivables (2021 - 2025)
Valion Bio has reported Change in Receivables over the past 5 years, most recently at $6000.0 for Q3 2025.
- For Q3 2025, Change in Receivables rose 185.71% year-over-year to $6000.0; the TTM value through Sep 2025 reached $5000.0, up 103.68%, while the annual FY2024 figure was -$105000.0, 256.72% down from the prior year.
- Change in Receivables for Q3 2025 was $6000.0 at Valion Bio, up from -$56000.0 in the prior quarter.
- Over five years, Change in Receivables peaked at $118000.0 in Q3 2023 and troughed at -$100000.0 in Q1 2024.
- A 5-year average of $250.0 and a median of -$2500.0 in 2021 define the central range for Change in Receivables.
- Biggest five-year swings in Change in Receivables: skyrocketed 700.0% in 2023 and later plummeted 222.58% in 2024.
- Year by year, Change in Receivables stood at -$2000.0 in 2021, then tumbled by 100.0% to -$4000.0 in 2022, then skyrocketed by 700.0% to $24000.0 in 2023, then surged by 129.17% to $55000.0 in 2024, then plummeted by 89.09% to $6000.0 in 2025.
- Business Quant data shows Change in Receivables for TIVC at $6000.0 in Q3 2025, -$56000.0 in Q1 2025, and $55000.0 in Q4 2024.